Marker Therapeutics Inc
Research Marker Therapeutics Inc (MRKR) on Bullrun: market cap USD 25.34M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMRKR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 25.34M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 3.18M
- Free cash flow-USD 7.92M
Valuation Snapshot
latest market cap is USD 25.34M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 3.55M | -USD 12.16M | -USD 12.01M | n/a | -0.79 | USD 16.07M | n/a | USD 16.80M |
| FY2024 | USD 6.59M | -USD 10.73M | -USD 10.91M | n/a | -1.19 | USD 19.19M | n/a | USD 18.56M |
| FY2023 | USD 3.31M | -USD 8.24M | n/a | n/a | -0.94 | USD 15.11M | USD 0 | USD 14.05M |
| FY2022 | USD 3.51M | -USD 29.93M | n/a | n/a | -3.58 | USD 11.78M | USD 7.62M | USD 19.60M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 25.34M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 24.84M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 33.30M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 48.89M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 23.06M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 78.93M | n/a | n/a | n/a |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Marker Therapeutics Inc's market cap?
Marker Therapeutics Inc's market capitalization is USD 25.34M.
What does Marker Therapeutics Inc do?
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.